The UK and Germany’s medical cannabis markets both more than doubled in size throughout 2025, once again cementing the countries as the engine behind European market growth.
Their runaway growth, according to Prohibition Partners‘ newly released Global Medical Cannabis Market Review 2026, continues to be driven by the growing prominence of telemedicine clinics.
Despite the success of the now ubiquitous telemedicine model in these markets, the report suggests that its prevalence does not necessarily equal success.
Australia, now one of the largest medical cannabis markets on the planet, with an estimated patient base of between 700,000 and 900,000, grew a modest 8% over the same period despite telemedicine dominating the market.
Released today and free to download now, Prohibition Partners’ latest report examines the emerging global shifts in supply, exports and patient markets, offering not only exclusive data on but actionable explanations of the dynamics behind the numbers.
Below, we’ve covered some key insights from the free report and available data packs.
Germany: 155% growth driven by Medical Cannabis Act
Germany is the largest medical cannabis market outside of North America, with estimated sales reaching nearly $1 billion by 2025. This represents a significant 155% growth compared to 2024, highlighting the substantial impact of the Medical Cannabis Act, which took effect on April 1, 2024.
The market’s expansion is driven by private prescriptions and telemedicine services. However, it remains uncertain whether the government will implement proposed telemedicine restrictions. Depending on the extent of these restrictions, they could have a considerable negative effect on market growth.
UK: Affordable telemedicine clinics drive 104% expansion
Compared to 2024, the UK’s medical cannabis market grew an estimated 104% in 2025, with sales reaching an estimated $298 million. The growth is driven by the growing awareness of medical cannabis among the public and health practitioners, as well as affordable private telemedicine clinics providing access to the general public.
Australia: Growth slows to 8% despite large patient base
In 2025, medical cannabis sales in Australia are projected to reach approximately $656 million. While Australia has one of the largest medical cannabis markets with an estimated patient base of 700,000 to 900,000, the market experienced only 8% growth compared to 2024.
This slower growth may indicate a gradual levelling off after several years of strong expansion. Furthermore, if health authorities implement proposed restrictions on patient access pathways and telemedicine services, the market could face a significant decline.
Source: Prohibition Partners Estimates 2026 (US Dollars)
Poland: Telemedicine restrictions drive 18% market contraction
In 2025, Poland’s medical cannabis market was estimated to reach $68 million, an 18% decline from the previous year. The declining growth was driven by the implementation of telemedicine restrictions for medical cannabis prescriptions in November 2024.
Although prescription numbers fell by more than 50% in the first months following the ruling, they have rebounded, driven by the introduction of in-person hybrid clinic models that reach patients throughout the country.
Israel: Canadian import debate continues
In 2025, Israel’s medical cannabis sales reached an estimated $372 million, with imports hitting a record high of 30.1 tonnes. The majority of these imports came from Canada, which has become a contentious issue for domestic cultivators.
Accusations of dumping practices by Canadian suppliers prompted calls from local producers for restrictions and tariffs. However, after a government review, Israel’s Finance Minister, Bezalel Smotrich, decided against implementing tariffs. He argued that such a levy could harm the growth of the domestic market and negatively affect patients by increasing product prices.
Brazil: New regulations pave way for domestic production
In 2025, the Brazilian medical cannabis market saw 45% year-on-year growth versus 2024. Brazil already has one of the world’s largest medical cannabis patient populations, yet access to affordable treatment remains out of reach for many. Domestic production has been extremely limited up to this point, with most products imported on a case-by-case basis, significantly driving up costs for patients.
New regulations passed in early 2026 have paved the way for market expansion. Brazil’s health regulator, Agência Nacional de Vigilância Sanitária (Anvisa), has introduced a new framework establishing three regulatory pathways for cannabis cultivation: commercial cultivation in secure facilities limited to 0.3% THC, unrestricted cultivation for scientific research authorised at the institutional level, and a pilot model allowing selected patient associations to cultivate under direct regulatory supervision.
The reforms also update rules for cannabis-based products, expanding approved administration routes, allowing pharmacy compounding on individual prescriptions, and widening access to higher-THC treatments for patients with severe chronic and debilitating conditions.
The Global Medical Cannabis Market Review 2026 is available for free download from Prohibition Partners. Enhanced data packages with market sizing and product and pricing analyses are available for the UK and Germany.
